1. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical angiographic and therapeutic profile. J Am Coll Cardiol 19:926–9351992.
2. Ellis SG, Roubin GS, King SB III, Douglas JS, Weintraub WS, Thomas RG. Angiographic and clinical predictors of acute closure after native coronary angioplasty. Circulation 77:372–3791988.
3. Jeong MH, Owen WG, Staab ME, Srivatsa SS, Sangiorgi G, Stewart ML. Porcine model for stent thrombosis. Cathet cardiovasc Diagn 38:38–431996.
4. Harker LA. Role of platelets and thrombosis in mechanism of acute occlusion and restenosis after angioplasty. Am J Cardiol 60:20B–28B1987.
5. Schwartz L, Bourassa MG, Lesperance B. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal angioplasty. N Eng J Med 318:1714–17191988.
6. Kim NH, Jeong MH, Cha KS, Bae Y, Ahn YK, Park JH, Cho JG, Park JC, Kang JC. The effects of therapeutic duration of combined antiplatelets, aspirin and ticlopidine on stent restenosis. Korean Circulation J 28:373–3811998.
7. Tenaglia AN, Fortin DF, Califf RM, Frid DJ, Nelson CL, Gardner L. Predicting the risk of abrupt vessel closure after angioplasty in an individual patients. J Am Coll Cardiol 24:1004–10111994.
8. EPIC (Evaluation of 7E3 in Preventing Ischemic Complications) Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956–9611994.
9. EPILOG (Evaluation in PTCA to improve Long-Term outcome GP IIb/IIIa Blockade Study Group) Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689–16961997.
10. CAPTURE (C7E3 Fab Antiplatelet Therapy in Unstable Refractory angina) Investigators). Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349:1429–14351997.
11. Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Sings and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338:1488–14971998.
12. Park WS, Jeong MH, Kim NH, Ahn YK, Bae Y, Gill GC. Successful coronary intervention with the aid of abciximab (ReoPro®) in high risk patients. J Kor Critical Care Med 13:254–2601998.
13. Kim W, Jeong MH, Kim KH, Park JC, Lee SH, Rhew JY, Kang KT, Kim NH, Kim KH, Ahn YK, Cho JG, Park JC, Kang JC. The rescue use of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab; ReoPro
®) in high-risk patients with acute myocardial infarction who underwent percutaneous coronary intervention. Korean Circulation J 31:492–4992001.
14. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–2341998.
15. Gowda MS, Vacck JL, Hallas D. One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty. Am J Cardiol 81:1067–10711998.
16. Carrozza JP, Ho KK, Neimann D, Kuntz RE, Cutlip DE. Diabetes mellitus is associated with adverse 6-month angiographic and clinical outcome following coronary stenting (abstr). Circulation 98:1–791998.
17. Marso SP, Ellis SG, Bhatt DL, Sapp SK, Emanuelsson H, Topol EJ. The stenting in diabetics debate: insight from the large GUSTO-IIb experience with extended follow-up (abstr). Circulation 98:1–781998.
18. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 78:486–5021988.
19. Weitz J, Bates S. Beyond heparin and aspirin: new treatments for unstable angina and non-Q wave myocardial infarction. Arch Intern Med 160:749–7582000.
20. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Circulation 80:198–2051989.
21. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrik K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 130:877–8921995.
22. Nakada MT, Jordan RE, Knight DM. Abciximab (ReoPro
®, chimeric 7E3 Fab) cross-specificity with [alpha] V [beta]3 integrin receptors: a potential mechanism for the prevention of restenosis. J Am Coll Cardiol 29:A243. 1997.
24. EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352:87–921998.
25. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:1434–14351994.
26. Cura Fernando A, Bhatt Deepak L, Lincoff A Michael, Kapadia Samir R. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 102:28–342000.
27. ERASER (Evaluation of Reo-Pro And Stenting to Eliminate Restenosis) Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. Circulation 100:799–8061999.
28. Kip KE, Faxon DP, Detre KM, Yeh WL, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94:1818–18251996.
29. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91:979–9891995.
30. Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus [Review]. Semin Thromb Hemost 17:422–4251991.
31. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20:166–1701990.
32. Tschope D, Schauseil S, Rosen P, Kaufmann L, Gries FA. Increased platelet volume: sign of impaired thrombopoiesis in diabetes mellitus. Klin Wochenscht 67:253–2591989.
33. Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease; The Framingham experience. Am Heart J 120:672–6761990.
34. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 28:573–5791996.
36. Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S. Elevated circulating R-selectin in insulin dependent diabetes mellitus. Thromb Haemost 76:358–3321996.
37. Davi G, Catalano I, Averna M, Notarbartolo A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769–17741990.
38. Morioka S, Makino H, Shikata K, Ota Z. Changes in plasma concentrations of vitronectin in patients with diabetes nephropathy. Acta Med Okayama 48:137–1421994.
39. Esser P, Bresgen M, Weller M, Heimann K, Wiedemann P. The significance of vitronectin in proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 232:477–4811994.
40. Davi G, Gennaro F, Spatola A, Catalano I, Averna M, Montalto G. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complications 6:7–111992.
41. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ. Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 92:1731–17361995.
42. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 97:1912–19201998.
43. Rozenman Y, Sapoznikov D, Mosseri M. Long-term angiographic follow-up of coronary ballon angioplasty in patients with diabetes mellitus: a due to the explanation of the results of the BARI study. Ballon Angioplasty Revascularization Investigation. J Am Coll Cardiol 30:1420–14251997.
44. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553–15591995.
45. Coleman KR, Braden GA, Willingham MC, Sane DC. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor, reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 84:1268–12761999.
46. Marso SP, Tanguay JF, Bhatt DL, Kleiman NS, Hammoud T. Optimizing the percutaneous coronary interventional strategy for diabetics-the EPISTENT experience (abstr). Circulation 98:400A. 1998.